Phase 4Terminated

Ursodeoxycholic Acid vs Metformin in Gestational Diabetes Mellitus (GUARD)

Randomised Controlled Trial of Gestational Treatment With Ursodeoxycholic Acid Compared to Metformin to Reduce Effects of Diabetes Mellitus

Sponsor
King's College London (Academic or other)
Enrollment
55 enrolled
Conditions
Gestational Diabetes
Interventions
Metformin; Ursodeoxycholic Acid
Ages
children, adults
Registry
NCT04407650

Full record on ClinicalTrials.gov

From the registry

GUARD is a Clinical Trial that wants to explore the impact of UDCA compared to metformin in the treatment of GDM. The trial wants to recruit 158 women who are overweight or obese who have been diagnosed with GDM, and require pharmacological treatment. Glucose control is our primary measure. Each year in the UK approximately 35,000 women develop diabetes during pregnancy, a condition called gestational diabetes mellitus (GDM), which increases the risk of adverse outcomes for both mother and child. Metformin, although unlicensed for used in pregnancy, is the most commonly used first line pharmacological treatment. However, there is increasing concern about its widespread use during pregnancy, because of its limited efficacy and because of potential safety concerns. Other common treatments have not been shown to be superior. Therefore, there is an unmet need for additional therapies. Ursodeoxycholic acid (UDCA) is commonly used in pregnancy for the treatment of intrahepatic cholestasis of pregnancy. It is currently not an established/licensed treatment for GDM. However data from…

Primary outcomes

  • Glycaemic Control

History

  1. Results first posted

  2. Last registry update

  3. Study completion

  4. Primary completion

  5. Started

  6. Registered